2023 was a year of transformative change and challenge across the global healthcare and life sciences industries. Drawing on PharmaBoardroom’s exclusive interviews and op-eds from across the world in 2023, our latest report tackles some of the year’s key regional trends. It includes everything from the landmark introduction of drug price negotiations in the US…
InFocus
With the tremendous healthcare momentum that is already underway in the Gulf Cooperation Council (GCC) countries, driven by economic diversification and transformation, the future of healthcare in the region looks bright. Government initiatives such as Saudi Arabia’s Health Sector Transformation Program, a vital component of the country’s economic and social reform roadmap, Vision 2030, coupled…
The global market for biosimilars has soared in recent years, driven by a push from healthcare systems across the world to take advantage of the savings that these products have to offer. This market stood at over USD 15 billion in 2020, having grown at a CAGR of 56 percent since 2015. Moreover, McKinsey estimates…
Home to the pharmaceutical heavyweights, Novartis and Roche, elite contract manufacturers and a dizzying array of acclaimed research institutions and medical institutes, Switzerland has long stood proud as a true powerhouse in medical discovery, drug development, and pharma manufacturing. Famed as an early-adopter market with capabilities spanning the entire life science value chain and ever…
Asia is at the forefront of new trends in precision medicine, from pioneering work in molecular diagnostics to increasingly tailored solutions in the war against cancer and in-depth genomic data sets better representing the profiles and needs of the region’s population. This second edition of InFocus Precision Medicine in Asia features insights from some of…
Long dismissed as the backwaters of healthcare innovation, the tremendous value of vaccines – the single most cost-effective health intervention after clean water – made itself starkly clear in 2020, as the discovery of a novel coronavirus quickly exploded into a full-blown global pandemic that rages on still. While billions have since been poured into…
In our second edition of InFocus Five Biotechs to Watch in China, we profile five biotech companies that have all found their own differing routes to success. While it is always tricky to define the starting point of a revolution, the Chinese biopharma boom – whether one considers the genesis to be the government’s public…
From how Asian countries can reclaim their ‘genetic destiny’ to an exploration of the ethnic differences in disease like cancer, diabetes and Hepatitis C, to some of the most exciting thematics including molecular diagnostics technology as well as cell and gene therapies, to spotlights on some of the most intrepid and innovative companies in the…
This inaugural edition of the InFocus Five Biotechs To Watch in China has selected companies at different stages of the biotech journey in order to showcase the diverse and multifaceted nature of Chinese biopharma innovation. While these companies are no doubt bound by a number of similarities, it is the differences that make their individual…
Produced in association with Novartis, InFocus Cell & Gene Therapy examines the remarkable progress of cell and gene therapies in recent years. Fast turning into a powerful engine of value creation for drug makers and representing a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses, in the last…
Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late. This special report delves into the flurry of activity taking place across the rare disease and orphan drug sector…
While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of scientific advancement in medicine – symbolized by recent radical breakthroughs in all manners of domains from stem cells and CAR-T generation immunotherapy to gene tech and 3D bio-printing – it is clear that regulatory science has struggled to…
